[
  {
    "ts": "2026-02-23T13:04:00+00:00",
    "headline": "Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer",
    "summary": "Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 BEERSE, BELGIUM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an extension of the RYBREVANT®▼ (amivantamab) marke",
    "url": "https://finance.yahoo.com/news/subcutaneous-rybrevant-amivantamab-approved-european-130400927.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "8e9634e1-8bd1-38d3-99aa-4508191b32f9",
      "content": {
        "id": "8e9634e1-8bd1-38d3-99aa-4508191b32f9",
        "contentType": "STORY",
        "title": "Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer",
        "description": "",
        "summary": "Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 BEERSE, BELGIUM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an extension of the RYBREVANT®▼ (amivantamab) marke",
        "pubDate": "2026-02-23T13:04:00Z",
        "displayTime": "2026-02-23T13:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3",
          "originalWidth": 2690,
          "originalHeight": 510,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFgHjEGtPkqKstjJ7xH84w--~B/aD01MTA7dz0yNjkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 2690,
              "height": 510,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m.9C60wTcxkvOQOLX1h8uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/subcutaneous-rybrevant-amivantamab-approved-european-130400927.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/subcutaneous-rybrevant-amivantamab-approved-european-130400927.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:00:00+00:00",
    "headline": "Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia",
    "summary": "CAMBRIDGE, Mass., February 23, 2026--Blackstone Life Sciences (\"BXLS\") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (\"AML\"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types.",
    "url": "https://finance.yahoo.com/news/blackstone-life-sciences-announces-co-120000684.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3ce00049-e712-3afb-bf7f-73b66c540d39",
      "content": {
        "id": "3ce00049-e712-3afb-bf7f-73b66c540d39",
        "contentType": "STORY",
        "title": "Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia",
        "description": "",
        "summary": "CAMBRIDGE, Mass., February 23, 2026--Blackstone Life Sciences (\"BXLS\") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (\"AML\"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types.",
        "pubDate": "2026-02-23T12:00:00Z",
        "displayTime": "2026-02-23T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/4e0f92f9f1be137647745a988c258cfa",
          "originalWidth": 1651,
          "originalHeight": 646,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qzK6W3y3294Z9uOP76VnWQ--~B/aD02NDY7dz0xNjUxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4e0f92f9f1be137647745a988c258cfa.cf.webp",
              "width": 1651,
              "height": 646,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g5nC8Ub2YNiw_oqt9qfprA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4e0f92f9f1be137647745a988c258cfa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/blackstone-life-sciences-announces-co-120000684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/blackstone-life-sciences-announces-co-120000684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]